Company Addex Therapeutics Ltd

Equities

ADXN

CH0029850754

Biotechnology & Medical Research

Delayed Swiss Exchange 09:08:18 2024-03-28 am EDT 5-day change 1st Jan Change
0.0956 CHF -1.65% Intraday chart for Addex Therapeutics Ltd +9.89% +107.83%

Business Summary

Addex Therapeutics Ltd is a Switzerland-based clinical-stage pharmaceutical company. The Company focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company's clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. It also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson's disease and mGlu3 PAM for neurodegenerative disorders.

Number of employees: 24

Sales per Business

CHF in Million2021Weight2022Weight Delta
Small-molecule Pharmaceutical Products
100.0 %
3 100.0 % 1 100.0 % -54.18%

Sales per region

CHF in Million2021Weight2022Weight Delta
Switzerland
100.0 %
3 100.0 % 1 100.0 % -54.18%

Managers

Managers TitleAgeSince
Founder 56 01-12-31
Director of Finance/CFO 38 17-05-31
Chairman 75 09-04-15
Chief Tech/Sci/R&D Officer 67 16-11-27
Corporate Officer/Principal - 02-07-31

Members of the board

Members of the board TitleAgeSince
Director/Board Member 54 18-05-31
Founder 56 01-12-31
Chairman 75 09-04-15
Chief Tech/Sci/R&D Officer 67 16-11-27
Director/Board Member 47 17-12-31
Director/Board Member 79 08-04-30

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 184,354,496 91,845,495 ( 49.82 %) 61,561,142 ( 33.39 %) 49.82 %

Shareholders

NameEquities%Valuation
44,113,438 23.93 % 3 M CHF
Tim Dyer
9.139 %
16,848,979 9.139 % 1 M CHF
NEA Management Co. LLC
3.064 %
5,648,690 3.064 % 401 565 CHF
Armistice Capital LLC
2.198 %
4,051,770 2.198 % 288 040 CHF
1,755,612 0.9523 % 124 806 CHF
New Leaf Venture Partners LLC
0.8665 %
1,597,444 0.8665 % 113 562 CHF
1,484,231 0.8051 % 105 514 CHF
1,464,834 0.7946 % 104 135 CHF
Ray Hill
0.4326 %
797,563 0.4326 % 56 699 CHF
Herculis Partners SA
0.2737 %
504,593 0.2737 % 35 872 CHF
NameEquities%Valuation
J. Stern & Co. LLP
0.3509 %
107,827 0.3509 % 1 M CHF
Armistice Capital LLC
0.1399 %
43,000 0.1399 % 408 930 CHF
NEA Management Co. LLC
0.0293 %
9,000 0.0293 % 85 590 CHF
Goldman Sachs & Co. LLC (Private Banking)
0.000335 %
103 0.000335 % 980 CHF

Holdings

NameEquities%Valuation
44,113,438 23.93% 3,136,024 $

Company contact information

Addex Therapeutics Ltd.

9, Chemin des Mines Plan-les-Ouates

1202, Geneva

+41 22 884 1555

http://www.addextherapeutics.com
address Addex Therapeutics Ltd(ADXN)